Work

Supplementary Figure 1 Legend from Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure 1 Legend. Median overall survival correlated with change in CA 19-9 (>50% decrease, versus {less than or equal to}50% decrease, or primary increase)

DOI: 10.1158/1078-0432.22455356.v1

Authors: Edward J. Kim, Vaibhav Sahai, Ethan V. Abel, Kent A. Griffith, Joel K. Greenson, Naoko Takebe, Gazala N. Khan, John L. Blau, Ronald Craig, Ulysses G. Balis, Mark M. Zalupski, Diane M. Simeone

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361910257

Cites:

Cited by:

Related to: 10